



Food and Drug Administration
Rockville MD 20857

#17

Re: Remodulin
Docket No.: 03E-0245

JAN 15 2004

The Honorable James E. Rogan
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Rogan:

This is in regard to the application for patent term extension for U.S. Patent No. 5,153,222, filed by United Therapeutics under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Remodulin, the human drug product claimed by the patent.

The total length of the regulatory review period for Remodulin is 4,026 days. Of this time, 3,443 days occurred during the testing phase and 583 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: May 15, 1991.

FDA has verified the applicant's claim that the date the investigational new drug application became effective was on May 15, 1991.

2. The date the application was initially submitted with respect to the human drug product under section 505(b) of the Federal Food, Drug, and Cosmetic Act: October 16, 2000.

FDA has verified the applicant's claim that the new drug application (NDA) for Remodulin (NDA 21-272) was initially submitted on October 16, 2000.


3. The date the application was approved: May 21, 2002.

FDA has verified the applicant's claim that NDA 21-272 was approved on May 21, 2002.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Jane A. Axelrad". The signature is fluid and cursive, with the first name "Jane" being the most prominent.

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Stephen Maebius
Foley & Lardner
Washington Harbor, Suite 500
3000 K Street, NW
Washington, DC 20007-5109